Company Active LTD

Company profile

Biodexa Pharmaceuticals (wales) Limited

Home - Biodexa Pharmaceuticals

Biodexa Pharmaceuticals (wales) Limited is a UK company with status active founded in 2003 based in Wales.

CRN
04929486
Founded
2003
Age
22

Overview

Legal name
BIODEXA PHARMACEUTICALS (WALES) LIMITED
Region
Wales
Registered address
1 CASPIAN POINT
CASPIAN WAY
CARDIFF
WALES
CF10 4DQ
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Biodexa Pharmaceuticals (wales) Limited
CRN 04929486
2
Direct and ultimate controller Active PLC

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

03 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

19 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 Nov
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ0NDI5NDg5M2FkaXF6a2N4

Published 20 Nov 2024 03:09

10 Oct
2003

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2012
Funded years
2012
Age at first award
8 years

Projects

2012 GRD Development of Prototype Lead participant

Development of Prototype for innovative sustained-release pharmaceutical manufacturing

1 Sep 2012 to 30 Nov 2014

Awarded
£249,963
Total cost £797,840

The Pharmaceutical industry has generally been slow to innovate in formulation technologies. Most medicines are still introduced to the body through the oral (tablets or capsules), intravenous (soluble liquid formulations) or intra-muscular (insoluble emulsions) routes. All of these have disadvantages especially for the increasing number of patients who r...

2012 Feasibility Studies Lead participant

Method for manufacture of biodegradable microsphere as matrices for control and stabilisation of aluminium containing vaccine adjuvants

1 Aug 2012 to 30 Nov 2012

Awarded
£24,975
Total cost £33,300

In this proposal, Q Chip is seeking to address a major obstacle for the production & distribution of vaccines. Whilst vaccination programmes have substantial benefits for global health, it is estimated that up to 50% of vaccine stocks are wasted due to lapses in storage conditions; aluminium adjuvant crystals (an essential component of many vaccines) have...

Product types

Feasibility Studies GRD Development of Prototype